There is no evidence that the COVID-19 vaccination increases the incidence of Guillain-Barré syndrome, a rare neurological disorder in which the body’s immune system attacks the nerves, according to a Rutgers-led study.
Published in the journal Vaccine, a statistical analysis by a Rutgers-team found that there was not a significant association between any of the COVID-19 vaccinations currently offered and the disease. The team was led by Nizar Souayah, a professor of neurology at Rutgers New Jersey Medical School who mentored a group of Rutgers New Jersey Medical School students, in collaboration with other scientists.
In July 2021, the U.S. Food and Drug Administration issued a warning, based on early reports, that those receiving the Johnson & Johnson’s COVID-19 vaccine may be at a greater risk of developing the sometimes fatal disease.
COVID-19 vaccination during pregnancy was linked to a lower risk of neonatal intensive care unit (NICU) admission, stillbirth, and maternal SARS-CoV-2 infection and no additional risk of preterm birth, small for gestational age (SGA), low Apgar score, cesarean delivery, postpartum hemorrhage, or chorioamnionitis, finds a systematic review and meta-analysis published yesterday in JAMA Pediatrics.
Japanese researchers led the analysis of nine observational studies comparing the pregnancy outcomes of 81,349 women who received at least one COVID-19 vaccine dose with those of 255,346 unvaccinated peers through Apr 5, 2022. Average age was 32 to 35 years in the vaccinated group and 29.5 to 33 years in the unvaccinated group.
Among vaccinated women, 98.2% had received an mRNA vaccine (Pfizer/BioNTech, Moderna, or unstipulated), while 1.1% received a viral vector vaccine (Oxford/AstraZeneca or Johnson & Johnson), and 0.7% were undocumented.
In the six studies that reported the number of doses, 85.4% of women received two doses of an mRNA vaccine. Seven studies reported the timing of the first dose, with 5.9%, 46.3%, and 47.8% of women receiving their first dose during the first, second, and third trimester, respectively.
Pacific island nations suffered severe depopulation from introduced diseases as a consequence of contact with European vessels, a new study from The Australian National University (ANU) shows.
The research, published in the Journal of Archaeological Science, indicates population declines were a lot larger than previously thought.
According to the study, the main island of Tonga had a population decline of between 70-86 per cent once Europeans made contact.
Researchers from the ANU School of Culture, History & Language, PhD candidate Phillip Parton and ARC Future Fellow Professor Geoffrey Clark, found there were between 100,000-120,000 people in Tonga prior to European contact.
“I and my co-author used aerial laser scanning data to map residences on the main island of Tonga and then used archaeological data I collected as part of my PhD to estimate the population,” Mr Parton said.
“This improved understanding of the past has allowed us to show a significant population decline from 50,000-60,000 to 10,000 during a 50-year period on the main island of Tongatapu in the Kingdom of Tonga.
Wagamaga OP t1_ir6j2h5 wrote
Reply to Scientists have found there is no evidence that the COVID-19 vaccination increases the incidence of Guillain-Barré syndrome, a rare neurological disorder in which the body’s immune system attacks the nerves by Wagamaga
There is no evidence that the COVID-19 vaccination increases the incidence of Guillain-Barré syndrome, a rare neurological disorder in which the body’s immune system attacks the nerves, according to a Rutgers-led study.
Published in the journal Vaccine, a statistical analysis by a Rutgers-team found that there was not a significant association between any of the COVID-19 vaccinations currently offered and the disease. The team was led by Nizar Souayah, a professor of neurology at Rutgers New Jersey Medical School who mentored a group of Rutgers New Jersey Medical School students, in collaboration with other scientists.
In July 2021, the U.S. Food and Drug Administration issued a warning, based on early reports, that those receiving the Johnson & Johnson’s COVID-19 vaccine may be at a greater risk of developing the sometimes fatal disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393181/